Menu
Recruiting NCT05996016

Gut and Vaginal Microbiota Profile Study for HIV Women

Observational HPV HIV Infections Vaginal Microbiota

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: HPV, HIV Infections, Vaginal Microbiota. Basic parameters: from 14 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Cohort Study Among HIV Infected Women:Exploring the Regulatory Mechanism of Gut and Vaginal Microbiota in HPV Infection and Cervical Lesion

Overview

Women Living with HIV Infection (WLHIV)are intended to acquire HPV infection which usually contributes to variable cervical lesions. we hypothesize that vaginal microbiota imbalance may make WLHIV prone to HPV infection,thereafter results in severe cervical lesion.

Detailed description

Women Living with HIV Infection (WLHIV)are intended to acquire HPV infection which usually contributes to variable cervical lesions. Besides the HPV co-infection, microbiota study recently reveals that the changes of vaginal bacteria spectrum might also be related with cervical disease in WLHIV. However, data on HPV prevalence in WLHIV and its associated cervical lesion incidence is still limited in China. Moreover, the causal relationship between vaginal microbiota and cervical lesion in WLHIV is not clear. Here, we hypothesize that vaginal microbiota imbalance may make WLHIV prone to HPV infection,thereafter results in severe cervical lesion.

Interventions

  • Other

Primary outcome measures

  • HPV infection incidence [Time frame: 0, 6m, 12m, 24m, 36m]
  • cervical lesions [Time frame: 0, 6m, 12m, 24m, 36m]

Eligibility criteria

Inclusion criteria

  • HIV women (including pregnant);
  • sign consent paper

Exclusion criteria

  • virgin or maiden

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Peking Union Medical College Hospital — Beijing

Identifiers

NCT: NCT05996016 · PekingUMCH-K2675

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗